CA-SCIENTIST.COM
1.4.2021 13:57:06 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading marketplace for life science research, announced today that it has partnered with Charles River , Certis Oncology and other leading oncology CROs to launch a Disease Model Finder that helps medical researchers use genetic, cellular and patient data to find the most appropriate research models for their preclinical development projects.
“Our proprietary model selection software uses multiple machine learning algorithms to help researchers sift through large amounts of data and identify in vitro and in vivo models for their research,” stated Javier Pineda, PhD, Data Scientist at Scientist.com. “Scientists can filter by gene mutation, gene expression, cancer type or patient information, and then purchase without delay once the right model is identified.”
The Disease Model Finder brings together a wealth of data that can help scientists choose the right preclinical disease models. DNA sequencing data from CRO partners is uploaded and analyzed so that researchers can easily search for models based on the presence (or absence) of a mutated gene or by the up or down regulation of gene expression. Marketplace customers can then filter their search results based on cancer type, subtype and characteristics or patient information.
“Scientist.com’s new Disease Model Finder will enable pharma and biotech researchers to find and purchase the most appropriate Charles River models for their drug development programs,” said Melissa Schroeder, E-Commerce Manager at Charles River. “Having access to advanced data that better matches a patient-derived xenograft (PDX) model with a research program will enable optimal study design, ultimately saving time and money as clients race to get critical therapies to patients.”
At launch, the Disease Model Finder includes 650 PDX models provided by Charles River, Certis, XenTech , the Lab for Innovated Diagnosis and Experimental Therapeutics (LIDE) and others—a number that is projected to grow quickly as more CROs join the program. By 2022, the platform will include other model systems including organoids, cell-derived xenografts (CDX), syngeneic models, immunoncology models and patient-derived cell lines.
“With so many drugs failing in human clinical trials because they don’t work, it is imperative that we use more predictive preclinical models of disease,” stated Peter Ellman, Certis Oncology CEO. “By combining gene analysis, patient data and tissue profiling data, Scientist.com’s Disease Model Finder increases the odds that researchers are selecting the right Certis models for translational drug development.”
To learn more please visit https://www.scientist.com/disease-model-finder/
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM to Drive AI-Powered Modernization of IT Infrastructure and Application Support for UK-based SSP Group26.5.2026 11:00:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has entered a strategic partnership with SSP Group, a leading operator of food and beverage outlets in travel locations worldwide. Through this AI-powered partnership, LTM will deliver modernized, end-to-end IT infrastructure support and enhanced application maintenance services to SSP Group. As part of this engagement, LTM will leverage its advanced AI capabilities including its BlueVerseTM ecosystem to help SSP manage operational risks, simplify infrastructure and application complexities, and drive business efficiency and agility. Additionally, the collaboration will focus on enabling data-driven decision-making, accelerating innovation through automation, delivering scalable solutions that enhance customer experience, and driving cost optimization through AI automation and simplification. “As we continue to advance our IT capabilities, having a trusted partner like LTM with deep domain expertise and a focus on
ROYC and Stilla Enter Strategic Partnership to Operationalise Agentic AI in Private Markets26.5.2026 10:30:00 CEST | Press release
ROYC today announced a partnership with Stilla.ai as the platform layer where ROYC will create, share and run its internally developed AI skills and agents. This operationalises the agentic AI strategy ROYC set out earlier, equipping every function across the company with the tools and resources to build and deploy their own AI agents and converting this into measurable productivity gains and accelerated product development. This will substantially accelerate launch of new platform features, improving cost efficiency at the same time as strengthening overall governance and oversight. For ROYC’s customers and partners, the result will be shorter time-to-market for new product releases, shorter time frames moving from idea to productification and tailored customer experience from an investor services perspective. “Our strategy is clear: AI is embedded in every aspect of our ways of working and what the ROYC Operating System does, not a side project,” said Peter Bergenwald, CTO of ROYC. “
IQOS One of the Most Valuable Global Brands, According to Kantar’s BrandZ 2026 Ranking26.5.2026 10:00:00 CEST | Press release
Recognition reinforces the growing consumer relevance of IQOS and the strength of Philip Morris International’s smoke-free vision Philip Morris International’s (PMI) (NYSE: PM) IQOS, the #1 tobacco heating system1, has been listed for the first time as one of the top 100 most valuable brands in the world in Kantar’s BrandZ 2026 Most Valuable Global Brands. This ranking solidifies IQOS’s global momentum and its emergence as a culturally relevant, iconic brand for adult nicotine users seeking better alternatives to cigarettes. According to the BrandZ 2026 Most Valuable Global Brands, IQOS achieved a ranking of #74 globally. With more than 35 million IQOS users worldwide—most of whom have fully switched away from cigarettes2—the brand continues to lead from the front and champion in a smoke-free era through science-backed innovation and consumer-centric design. Within 10 years of inception, IQOS surpassed $10 billion in annual net revenues, reaching this milestone faster than some of the
Quectel Expands EMEA Reach With Future Electronics Distribution Agreement26.5.2026 10:00:00 CEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announced an expanded distribution partnership with Future Electronics to bring its full portfolio of products and services to customers across the EMEA region. Under this agreement, Future Electronics will bring Quectel’s full IoT portfolio to customers across Europe, the Middle East and Africa, with a strong focus on its non-cellular solutions, including antennas, GNSS, Wi-Fi, Bluetooth and smart modules. This collaboration marks a significant step in strengthening Quectel’s presence in EMEA, leveraging Future Electronics’ strong regional infrastructure, technical expertise, and established customer relationships to accelerate growth and innovation. “Future Electronics’ extensive footprint and demand creation capabilities make them an ideal partner for expanding our reach across EMEA,” said Natasha Barrios, Senior Vice President, EMEA, Quectel Wireless Solutions. “By working together, we can ensure faster a
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 09:00:00 CEST | Press release
Kvvit to lead local development, regulatory activities and commercialization of INBRIJA® in mainland China, Hong Kong and Macao Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao. Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercializat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom